Inovio Pharmaceuticals Inc (INO)

[surf1944]

4:03AM Inovio Pharma's universal Avian Flu vaccine generates protective antibody responses against six H5N1 viruses in Phase I trial (INO) 0.48 : Co announces that its SynCon avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial, a distinct clinical achievement on Inovio's path to develop universal influenza vaccines. By design, Inovio's SynCon? flu vaccine is not matched to any single virus. Importantly, the vaccine generated a hemagglutination inhibition titer of 1:40 or higher against at least one of the six tested H5N1 strains in 8 of 17 (47%) immunized subjects, demonstrating the vaccine's broad coverage; 12 of 17 (71%) vaccines generated an HAI titer of 1:20 or higher, indicating a positive vaccine response, against at least one H5N1 strain.